Starpharma today announced positive interim results from its ongoing phase 2 trial of DEP^® cabazitaxel, showing that 100% (22/22) of evaluable patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.

AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, showcasing AstraZeneca’s first DEP^® oncology product, AZD0466.